Tuesday, June 07, 2022 4:09:22 PM
Howard Kim
May 20, 2022,
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Inhibikase Therapeutics (IKT – Research Report), with a price target of $6.00. The company’s shares closed last Friday at $0.63, close to its 52-week low of $0.62.
According to TipRanks.com, Roy is a 3-star analyst with an average return of 3.7% and a 29.7% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Inhibikase Therapeutics is a Moderate Buy with an average price target of $6.00.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent IKT News
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 04/18/2024 08:30:00 PM
- Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension • GlobeNewswire Inc. • 04/03/2024 12:05:00 PM
- Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity • GlobeNewswire Inc. • 03/27/2024 08:15:20 PM
- Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 02/28/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 12:59:02 PM
- Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers • GlobeNewswire Inc. • 02/07/2024 12:55:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/01/2024 09:49:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:09:53 PM
- Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib • GlobeNewswire Inc. • 01/29/2024 02:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:31:03 PM
- Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli • GlobeNewswire Inc. • 01/16/2024 09:05:00 PM
- Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs • GlobeNewswire Inc. • 12/19/2023 01:30:00 PM
- Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro • GlobeNewswire Inc. • 12/04/2023 01:35:00 PM
- Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity • GlobeNewswire Inc. • 11/14/2023 09:30:06 PM
- Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 02:28:32 PM
- Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023 • GlobeNewswire Inc. • 11/07/2023 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 10/16/2023 09:24:04 PM
- Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment • GlobeNewswire Inc. • 10/16/2023 11:00:27 AM
- Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy • GlobeNewswire Inc. • 10/04/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2023 03:23:58 PM
- Inhibikase Therapeutics Announces Development of Novel Formulation of risvodetinib • PR Newswire (US) • 08/24/2023 12:30:00 PM
- Inhibikase Therapeutics to Present at the International Congress of Parkinson's Disease and Movement Disorders • PR Newswire (US) • 08/22/2023 12:05:00 PM
- Inhibikase Therapeutics Initiates Development of Second Generation c-Abl inhibitors and names IkT-148009 as risvodetinib • PR Newswire (US) • 08/21/2023 12:30:00 PM
- Inhibikase Therapeutics Announces Completion of the 501 Bioequivalence Study of IkT-001Pro • PR Newswire (US) • 08/17/2023 12:30:00 PM
VPR Brands LP Reports Record Annual Financial Performance for Fiscal Year 2023 • VPRB • Apr 19, 2024 11:24 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM